AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
ApexOnco Front Page
Recent articles
A son of glembatumumab vedotin has just started its phase 1 study.
J&J decides not to opt in to erzotabart, and Genmab pulls the plug.
A hit on EFS will challenge regulators, and points to Merck's design blunder in Keynote-585.
Could a new ADC project distract attention away from evorpacept?
The German group has posted a PFS win in phase 3, but overall survival was confounded by crossover.
Merck & Co gives up on Agenus, while Sanofi hands BND-22 back to Biond.
A Chinese phase 3 trial of the partners’ B7-H4-targeting ADC has just begun.
